← Back to Search

PET/MRI Brain Imaging for Alzheimer's Disease (PiB ADC Trial)

Phase 2
Recruiting
Led By Jonathan McConathy, MD
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

Summary

This trial uses a special imaging dye to detect harmful protein build-up in the brains of participants from the UAB Alzheimer's Disease Center. The study aims to understand how these brain changes relate to race, vascular risk factors, and cognitive health. The dye helps make these harmful proteins visible in brain scans.

Who is the study for?
This trial is for participants already enrolled in the UAB Alzheimer's Disease Center study. It's focused on those who can undergo PET/MRI scans and do not have severe dementia that would prevent participation. Women of childbearing potential must test negative for pregnancy.
What is being tested?
The study aims to measure amyloid deposits in the brain using a PET tracer called [C-11]PiB. It will explore how race and vascular risk factors interact with these amyloid levels and cognitive status.
What are the potential side effects?
Since this is an imaging study, side effects are minimal but may include discomfort from lying still during scanning, reactions to contrast agents used (if any), or claustrophobia inside the scanner.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Amyloidosis

Trial Design

1Treatment groups
Experimental Treatment
Group I: [C-11]PiB-PET/MRIExperimental Treatment1 Intervention
All participants in this study will undergo an amyloid-PET imaging using the tracer \[C-11\]PiB with a simultaneous PET/MRI system. The \[C-11\]PiB dosage is 300-670 MBq (8 - 18 mCi) given intravenously, and the PET/MRI imaging time is approximately 60 min.

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,621 Previous Clinical Trials
2,290,818 Total Patients Enrolled
Jonathan McConathy, MDPrincipal InvestigatorUniversity of Alabama at Birmingham
2 Previous Clinical Trials
225 Total Patients Enrolled

Media Library

[C-11]PiB-PET/MRI Clinical Trial Eligibility Overview. Trial Name: NCT03503331 — Phase 2
Alzheimer's Disease Research Study Groups: [C-11]PiB-PET/MRI
Alzheimer's Disease Clinical Trial 2023: [C-11]PiB-PET/MRI Highlights & Side Effects. Trial Name: NCT03503331 — Phase 2
[C-11]PiB-PET/MRI 2023 Treatment Timeline for Medical Study. Trial Name: NCT03503331 — Phase 2
~30 spots leftby Apr 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top